This study is looking at whether a drug called ivonescimab, given after standard radiation therapy (stereotactic body radiotherapy or SBRT), is an effective treatment for people with early-stage non-small cell lung cancer (NSCLC). Researchers want to see if ivonescimab can help you live longer without your cancer coming back. You might be able to join if you have NSCLC that is stage IA2-IIA, or certain stage IIB, and are at least 18 years old. The study is currently recruiting a small group of 36 participants.

Study design

This study plans to enroll 36 participants. It is an interventional study, meaning participants will receive a specific treatment.

What's involved

You would receive radiation therapy within 28 days of joining, followed by ivonescimab given intravenously (IV) every 3 weeks.

Compensation

Not stated in the trial record.

Follow-up

Researchers will follow participants for 24 months to measure how long they live without their cancer returning.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.